Navigation Links
New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
Date:5/9/2008

eir primary endpoints. The LITHE trial evaluating ACTEMRA in RA is an ongoing two-year study and is expected to report complete data evaluating the effects of ACTEMRA on the inhibition of structural joint damage in 2009. ACTEMRA is awaiting approval in the United States and Europe.

ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In April 2005, ACTEMRA was launched by Chugai in Japan as a therapy for Castleman's disease; in April 2008, ACTEMRA was approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis in Japan.

The serious adverse events reported in ACTEMRA clinical trials were serious infections and hypersensitivity reactions including anaphylaxis. The most common adverse events reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were seen in some patients; these increases were generally mild and reversible, with no hepatic injuries or any observed impact on liver function.

About IL-6

IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. If approved, ACTEMRA will be the first and only medication to specifically target IL-6 inhibition in patients with RA.

About Rheumatoid Arthritis

Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of R
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 ... economics and outcomes research also   to   be ... SHPG ), the global specialty biopharmaceutical company, ... poster presentations at the American Psychiatric Association (APA) 166th ... May 18-22. The data being presented represent Shire,s ongoing ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... , May 17, 2013 ... developer of oral drug delivery systems, announced today that ... cleared the Company,s Investigational New Drug application(IND) for ORMD-0801, ... pleased to have the FDA clearance to proceed," stated ... "The upcoming trial is a major milestone for Oramed ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... -- Winner Medical Group Inc. (Nasdaq: WWIN ... of medical dressings, medical disposables and non-woven fabric made ... that it will release financial results for its first ... opens. Winner Medical,s senior management will host a conference ...
... DETROIT, Jan. 30, 2011 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... million and $268.2 million in the third quarter and first ... to $52.0 million and $178.4 million, respectively, for the corresponding ... 31, 2009. During the third quarter and first nine months ...
Cached Medicine Technology:Winner Medical Group Inc. to Host First Quarter 2011 Earnings Conference Call on Thursday, February 10, 2011 at 08:30 a.m. EST 2Winner Medical Group Inc. to Host First Quarter 2011 Earnings Conference Call on Thursday, February 10, 2011 at 08:30 a.m. EST 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 7Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 8
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... May 19, 2013 The report “Feed ... Trends & Forecasts up to 2017” published by MarketsandMarkets, ... with analysis and forecasting of the global volume and ... the driving and restraining factors for the global market ... and challenges. The market is segmented and revenue is ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Americans live ... to the newest American Veterinary Medical Association (AVMA) U.S. ... American dog owners consider their dog a member of ... had said as much five years earlier. , According ... value of the national income dedicated to pets has ...
(Date:5/19/2013)... 2013 The Fat Loss Code program developed ... that help people get in shape, and gain a ... The program also is a natural fat loss system that ... author of this fat loss diet program claimed that The ... help people keep body fat off long-term. After Shawn Stevenson ...
(Date:5/19/2013)... 19, 2013 Agora Health Limited developed by ... guides on how to increase memory power naturally ... method that helps people re-new their entire health from the ... depression caused by a fatigued mind. In addition, the program ... for a lifetime. The author claimed that this program can ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Weight Loss Secrets | How “The Fat Loss Code” Helps People Gain A Healthy Life And Get In Shape - Health Review 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
... emergence of minimally invasive surgery procedures in operating theatres. ... leaves much to be desired. Researcher Magdalena Chmarra has ... training system which records and analyses the surgeon,s movements. ... time, an objective benchmark for measuring a surgeon,s basic ...
... ICU, and All-Private Hospital WingNEW ORLEANS, Jan. 12 At ... on Monday, January 12, 2009 , DHH Secretary Alan ... Ochsner Baptist Medical Center and the community to celebrate the ... room hospital wing at 2700 Napoleon Avenue in ...
... NEW YORK and SAN FRANCISCO, Jan. 12 ... the largest independent communications agency focused exclusively on ... focused on helping companies build health-based brands, today ... services agency that works with healthcare and technology ...
... AMERIGROUP Corporation (NYSE: AGP ) announced ... Institute, which will enhance the Company,s focus on improving ... are financially vulnerable, who have disabilities or who are ... a joint venture of AMERIGROUP Corporation and the AMERIGROUP ...
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... medical devices worldwide, today announced selected preliminary,unaudited results ... The,preliminary results reported below include the results ... Datascope ("DPM") starting from May,1, 2008. , ...
... Bioequivalence Study to Evaluate the Safety, Tolerability, and ... Laboratories, Inc, an emerging specialty pharmaceutical company dedicated ... in opioid pharmaceuticals, announced today the initiation of ... CL-108. "After many months, development in the ...
Cached Medicine News:Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2Health News:Ochsner Baptist Opens ER and Clara Wing 2Health News:Ochsner Baptist Opens ER and Clara Wing 3Health News:Ochsner Baptist Opens ER and Clara Wing 4Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 2Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 3Health News:AMERIGROUP to Establish Public Policy Institute 2Health News:AMERIGROUP to Establish Public Policy Institute 3Health News:Mindray Announces Preliminary 2008 Operating Results 2Health News:Mindray Announces Preliminary 2008 Operating Results 3Health News:Mindray Announces Preliminary 2008 Operating Results 4Health News:Charleston Laboratories, Inc. Phase I Clinical Trial 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: